Table 2.
Risk of cancer within 3 years of myositis onset with different MSAs compared to the general population
| Autoantibodies | Totala | Observedb | Expectedc | SIR (95% CI) |
|---|---|---|---|---|
| Anti-TIF1-γ | 89 | 34 | 1.97 | 17.28 (11.94, 24.14) |
| Anti-NXP2 | 42 | 3 | 0.37 | 8.14 (1.63, 23.86) |
| Anti-SAE1 | 13 | 4 | 0.31 | 12.92 (3.23, 32.94) |
| Anti-Mi-2 | 24 | 0 | 0.53 | 0 (0, 7.03) |
| Anti-HMGCR | 21 | 1 | 0.33 | 3.0 (0.30, 16.83) |
| Anti-SRP | 30 | 0 | 0.32 | 0 (0, 11.47) |
| Anti-MDA5 | 92 | 0 | 1.25 | 0 (0, 2.97) |
| Anti-Jo-1 | 63 | 3 | 1.01 | 2.98 (0.60, 8.74) |
| Anti-PL-7 | 33 | 0 | 0.71 | 0 (0, 5.24) |
| Anti-PL-12 | 17 | 2 | 0.34 | 5.92 (0.59, 21.31) |
| Anti-EJ | 22 | 0 | 0.40 | 0 (0, 9.36) |
| Anti-OJ | 1 | 0 | 0.06 | 0 (0, 58.78) |
| MSAs-d | 170 | 11 | 2.76 | 3.99 (1.96, 7.14) |
Abbreviations: SIR standardized incidence ratio, MSAs myositis specific autoantibodies
aNumber of autoantibody-positive patients
bObserved cancer cases within 3 years of myositis onset
cExpected cancer cases based on estimates in the general population in China, after adjustment for age and gender
dPatients who were negative for all of the MSAs listed